Inhibitors of the sodium-glucose cotransporter 2 (SGLT-2) have been shown to reduce blood glucose levels in subjects with T2DM by enhancing urinary glucose excretion (592). Here, SLC5A2 is linked to type 2 diabetes mellitus.